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Background: Myeloid cells are key players in the recognition and response of the host against invading viruses.
Paradoxically, upon HIV-1 infection, myeloid cells might also promote viral pathogenesis through trans-infection, a
mechanism that promotes HIV-1 transmission to target cells via viral capture and storage. The receptor Siglec-1
(CD169) potently enhances HIV-1 trans-infection and is regulated by immune activating signals present throughout
the course of HIV-1 infection, such as interferon α (IFNα).
Results: Here we show that IFNα-activated dendritic cells, monocytes and macrophages have an enhanced ability
to capture and trans-infect HIV-1 via Siglec-1 recognition of viral membrane gangliosides. Monocytes from untreated
HIV-1-infected individuals trans-infect HIV-1 via Siglec-1, but this capacity diminishes after effective antiretroviral
treatment. Furthermore, Siglec-1 is expressed on myeloid cells residing in lymphoid tissues, where it can mediate
viral trans-infection.
Conclusions: Siglec-1 on myeloid cells could fuel novel CD4+ T-cell infections and contribute to HIV-1 dissemination
in vivo.
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Antigen presenting cells of the myeloid lineage, such as
dendritic cells (DCs), monocytes and macrophages, initiate
antiviral immune responses and are crucial to control in-
vading viruses. On the other hand, myeloid cells may also
be productively infected with HIV-1 and thus promote
pathogenesis. Compared to activated CD4+ T cells, the per-
missivity of myeloid cells for HIV-1 is limited [1-3]. This is
largely due to restriction by the cellular factor SAMHD1 in
these cells [4,5]. Nevertheless, myeloid cells can contribute
to HIV-1 dissemination through the alternative pathway of
trans-infection of CD4+ T cells [6,7]. This mechanism in-
volves HIV-1 capture and uptake by myeloid cells and the
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unless otherwise stated.contact zone, the infectious synapse, that facilitates infec-
tion of CD4+ T cells [8].
We and others have previously shown that HIV-1 trans-
infection requires the sialic acid binding Ig-like lectin 1
(Siglec-1, Sialoadhesin or CD169) [9,10]. Siglec-1 is
expressed on the surface of DCs and other myeloid cells
[11,12] and recognizes sialyllactose molecules exposed on
HIV-1 membrane gangliosides [13,14]. Siglec-1 expression
on myeloid cells is induced by activating signals that are
present upon acute and chronic immune activation, which
is observed in HIV-1-infected patients [15,16]. Various
pro-inflammatory factors associated with HIV-1 disease
progression stimulate Siglec-1 expression on myeloid
cells. Lipopolysaccharide (LPS) is a component of the
bacterial cell wall that is significantly increased inis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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pletion of gastrointestinal CD4+ T cells, which causes
systemic translocation of bacteria from the intestinal
lumen [17]. In vitro, LPS is able to induce Siglec-1 expres-
sion on DCs, potently enhancing their capacity to trans-
infect HIV-1 [9]. Another factor is interferon alpha (IFNα)
that exerts antiviral effects on HIV-1 replication [10,18],
but also serves as a marker of poor clinical prognosis dur-
ing late-stage disease [19,20]. Although IFNα is produced
in large quantities by plasmacytoid DCs after HIV-1 chal-
lenge [21,22] the key cells responsible for sustained IFNα
production in vivo are currently under intensive reexami-
nation [23,24]. Regardless of its source, IFNα potently
induces the in vitro expression of Siglec-1 on myeloid
cells [10,18].
Siglec-1 up-regulation by immune activating signals
during HIV-1 infection could play an important role by
allowing myeloid trans-infection of multiple target cells.
This function could be particularly relevant in lymphoid
tissues, the major sites of HIV-1 replication, where mye-
loid cells migrate and repeatedly establish interactions
with CD4+ T cells [25-27], the primary targets of pro-
ductive HIV-1 infection. In the study described here, we
investigated whether Siglec-1 expression on myeloid
cells can be induced during chronic HIV-1 infection and
thus contribute to systemic viral dissemination. We
found that Siglec-1 on myeloid cells is up-regulated
in vitro by IFNα, allowing for HIV-1 capture and trans-
mission. In vivo, HIV-1 infection enhanced Siglec-1 ex-
pression on peripheral blood monocytes, but diminished
after effective antiretroviral treatment, reducing the
trans-infection capacity of monocytes. Moreover, Siglec-
1 is present on myeloid cells from lymphoid tissues,
where it can mediate HIV-1 trans-infection.
Results
Siglec-1 mediates HIV-1 capture by IFNα-treated myeloid
cells
Siglec-1 expression on the surface of myeloid cells can be
stimulated by IFNα [10,18] an antiviral cytokine released by
pDCs and possibly by other immune cells after HIV-1 in-
fection [21,22,24]. When we compared Siglec-1 expression
levels on distinct myeloid cells activated in the presence of
IFNα, we observed a 17-fold up-regulation in monocyte-
derived DCs and a twofold up-regulation in macrophages
and monocytes (Figure 1A).
We have previously reported that Siglec-1 expression
levels determine the capacity of DCs to capture HIV-1 [9].
To test whether this also holds true for monocytes and
macrophages, we first compared the density of Siglec-1
surface expression applying a quantitative FACS assay that
determines the absolute number of Siglec-1 antibody
binding sites. This number was highest in IFNα-activated
monocyte-derived DCs, followed by macrophages andmonocytes (Figure 1B). Next, we analyzed binding of in-
fectious HIV-1 to IFNα-activated myeloid cells. HIV-1 was
incubated with the cells for 4 h at 4°C to avoid viral intern-
alization and cell-associated p24Gag was quantified by
ELISA after extensive washing. Consistent with their re-
spective Siglec-1 expression levels (Figure 1B), IFNα-
activated monocyte-derived DCs showed a higher HIV-1
binding capacity than monocytes (Figure 1C). To investi-
gate whether this binding was specific for Siglec-1, cells
were pre-treated with a monoclonal antibody (mAb)
against Siglec-1. This treatment led to a reduction of HIV-
1 binding by 83% in all cases, while isotype control treat-
ment had no inhibitory effect (Figure 1D). Similar results
were obtained with fluorescent HIV-1 Virus-Like Particles
(VLPs), which lack the viral envelope glycoprotein but
carry sialyllactose-containing gangliosides recognized by
Siglec-1 (Additional file 1: Figure S1A-B). These data indi-
cate that Siglec-1 is the main molecule responsible for
HIV-1 capture by IFNα-activated myeloid cells, and that
its expression correlates with the viral binding capacity of
the respective cell type.
Siglec-1 mediates HIV-1 uptake into a storage
compartment and enhances HIV-1 trans-infection
specially in IFNα-treated monocytes and DCs
Having established Siglec-1-dependent virus binding in all
three types of myeloid cells, we performed uptake experi-
ments at 37°C to follow the fate of the bound virus. IFNα-
activated myeloid cells were incubated with HIV-1 for 4 h
at 37°C and cell-associated p24Gag was quantified by ELISA
after extensive washing (Figure 2A). Monocyte-derived
DCs and monocytes contained similar amounts of HIV-1,
while macrophages displayed lower uptake (Figure 2A).
Treatment with Bafilomycin A1, an inhibitor of lysosomic
degradation, only increased the level of cell-associated virus
in macrophages (Figure 2B). Thus, faster viral degradation
in macrophages accounts for the reduced cell-associated
virus observed in this cell type (Figure 2A). HIV-1 uptake
was strongly inhibited by a mAb against Siglec-1 in all
cases (Figure 2C). Similar results were obtained when
we performed uptake experiments with fluorescent
VLPs (Additional file 1: Figure S1C-D), with macro-
phages showing residual capture in the presence of the
mAb (Additional file 1: Figure S1D).
To elucidate the HIV-1 trafficking differences in macro-
phages compared to other myeloid cells, we investigated
viral uptake by confocal microscopy. IFNα-treated myeloid
cells were pulsed with fluorescent HIV-1Cherry for 4 h
at 37°C and subsequently stained with mAbs against
Siglec-1 and against HLA-DR to reveal cellular mem-
branes (Figure 2D, top images). While most of the
monocyte-derived DCs and monocytes accumulated
HIV-1Cherry within a sac-like compartment enriched in
Siglec-1, macrophages exhibited a more scattered
Figure 1 Siglec-1 mediates HIV-1 capture by IFNα-treated myeloid cells. A. Representative profiles of Siglec-1 staining in distinct myeloid cells cultured with
or without 1000 U/ml of IFNα and assessed by FACS. Staining of matched-isotype control is also shown. The mean fold increase in fluorescence after IFNα
treatment of cells derived from three donors is shown in red numbers. B. Mean number of Siglec-1 antibody binding sites per cell displayed by different
myeloid cells exposed to 1000 U/ml of IFNα for 48 h and assessed by quantitative FACS analysis. Data show mean values and SEM from four experiments
including cells from 12 donors. C. Comparative binding of HIV-1NL4–3 to different myeloid cells previously exposed to 1000 U/ml of IFNα for 48 h. Cells were
cultured with HIV-1NL4–3 for 4 h at 4°C, washed and lysed to measure p24
Gag by ELISA. Data show mean values and SEM from two experiments including
cells from six donors. D. Relative binding of HIV-1NL4–3 by different IFNα-treated myeloid cells that had been pre-incubated with 10 μg/ml of the indicated
mAbs before HIV-1 exposure for 4 h at 4°C as described in C. To compare the effect of the mAbs in different myeloid cells, values were normalized to the
level of HIV-1 binding by mock-treated cells (set to 100%). Data show mean values and SEM from two experiments including cells from six
donors. Statistical differences were assessed with a paired t test in B and C, and with a one sample t-test in D.
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Thus, the complementary approaches of confocal mi-
croscopy analysis and viral uptake experiments indicate
that Siglec-1 is essential for HIV-1 capture in all mye-
loid cells, while it is not sufficient for further down-
stream uptake and trafficking involved in the formation
of a condensed viral compartment.
We next assessed the capacity for HIV-1 trans-infection
by the different myeloid cell types. Cells were pulsed
with equal amounts of the X4-tropic HIV-1NL4–3
followed by extensive washing and were subsequently
co-cultured with a CD4+ reporter cell line for two
days. Monocyte-derived DCs had the highest capacity
for trans-infection followed by monocytes, while mac-
rophages showed only weak trans-infection capacity
(Figure 2E), consistent with their faster viral degrad-
ation kinetics (Figure 2B). However, trans-infection
depended on Siglec-1 in all cases (Figure 2F).Siglec-1 is up-regulated on monocytes from HIV-1-infected
individuals, and its expression is reduced upon successful
antiretroviral treatment
To explore whether Siglec-1 could be functionally im-
portant in vivo, we assessed Siglec-1 expression on blood
monocytes from HIV-1-infected individuals before and
after initiation of antiretroviral treatment (Table 1), and
compared them to HIV-1-negative individuals. When we
quantified the number of Siglec-1 Ab binding sites per
monocyte ex vivo we found that Siglec-1 expression was
significantly lower in HIV-1-negative individuals com-
pared to untreated HIV-1-infected individuals (Figure 3A;
6-fold difference, P = 0.0006). Furthermore, Siglec-1 ex-
pression was significantly higher in monocytes isolated
before antiretroviral treatment compared to monocytes
isolated after antiretroviral treatment from the same pa-
tients (Figure 3A; 7-fold difference, P = 0.0017), return-
ing to the levels showed by HIV-1-negative individuals.
Figure 2 Siglec-1 mediates HIV-1 uptake into a storage compartment and enhances HIV-1 trans-infection specially in IFNα-treated monocytes and DCs.
A. Uptake of HIV-1NL4–3 by different myeloid cells exposed to IFNα. Cells were cultured with HIV-1 to measure p24Gag by ELISA. Mean values and SEM from
four experiments include cells from 12 donors. B. Fold change in HIV-1NL4–3 uptake of cells treated with bafilomycin A1 compared to untreated cells. Mean
values and SEM include cells from three donors. C. Relative uptake of HIV-1NL4–3 by IFNα-treated myeloid cells pre-incubated with the indicated mAbs.
Values are normalized to the level of HIV-1 uptake by mock-treated cells (set at 100%). Mean values and SEM from two experiments include cells from
six donors. D. Confocal microscopy analysis of different IFNα-treated myeloid cells pulsed with HIV-1Cherry and stained for Siglec-1 (Alexa 488), HLA-DR
(Alexa 647) and DAPI. (Top) Representative viral pattern for each kind of myeloid cell analyzed, showing maximum fluorescence intensity
of four channels. (Bottom) Percentage of myeloid cells with distinct viral patterns: random distribution, polarized accumulation, and sac-like compartment
formation, as illustrated in the left drawing. Mean values of 50 cells from two different donors are shown. E. HIV-1 transmission from IFNα-treated myeloid
cells to a luciferase reporter CD4+ cell line. HIV-1 infection was determined by induced luciferase activity in relative light units (RLUs). Mean values and SEM
from four experiments include cells from 12 donors. F. Relative HIV-1 transmission from IFNα-treated myeloid cells pre-incubated with the indicated mAbs.
Values are normalized to the level of HIV-1 trans-infected by mock-treated cells. Mean values and SEM from two experiments include cells from six donors.
Statistical differences were assessed with a paired t test in A and E, and with a one sample t-test in B, C and F.
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Table 1 Characteristics of the HIV-1-infected men followed
longitudinally before and after initiation of antiretroviral
treatment that are shown in Figures 3 and 4
PRE/POST Antiretroviral treatment Number or Median (IQR)
Number of patients 16
Age (years) 36 (24–40)
Antiretroviral treatment regimen
Non-Nucleoside Reverse Transcriptase
Inhibitors
8
Protease Inhibitors 7
Integrase Inhibitors 1
Time from diagnosis to antiretroviral
treatment (months)
2 (1.5-5)
Time between samples (months) 11 (7–19)
CD4+ T-cell count (cells/μl)
PRE antiretroviral treatment 297 (239–316)
POST antiretroviral treatment 505 (401–597)
Plasma Viral Load (Log10 HIV RNA
copies/ml)
PRE antiretroviral treatment 5 (4.4-5.5)
POST antiretroviral treatment 1.7 (1.4-1.7)
Figure 3 Siglec-1 is up-regulated on monocytes of HIV-1-infected individuals, b
number of Siglec-1 Ab binding sites per cell displayed by monocytes iso
or after successful antiretroviral treatment (with an initial median of 297 CD4+ T
505 CD4+ T-cell count and 1.7 log10 HIV RNA copies/ml after treatment). Graph
HIV-1-infected individuals. Man Whitney t-test was used to compare dif
individuals. Paired t-test was used to assess differences between HIV-1-
B. Uptake of fluorescent VLPs by monocytes isolated from HIV-1-infected individ
were pulsed with VLPs for 3 h at 37°C and assessed by FACS. Graph shows m
1NL4–3 by monocytes isolated from HIV-1-infected individuals before and
37°C, washed and lysed to measure p24Gag by an ELISA. Graph shows mean va
monocytes to perform this assay. D. HIV-1 transmission from monocytes
treatment to a reporter CD4+ cell line cultured at a ratio 5:1. Cells were pulsed w
the same individuals of panel C.
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viduals for their capacity to take up VLPs. Consistent with
their higher expression of Siglec-1, cells isolated before anti-
retroviral treatment exhibited a higher uptake capacity
for VLPs compared to cells obtained under suppressive
therapy (Figure 3B; 19-fold difference, P = 0.0039).
Similar results were observed for uptake of complete
HIV-1 (Figure 3C). Consistent with the enhanced uptake,
HIV-1 trans-infection was also higher for cells taken before
antiretroviral treatment (Figure 3D, P = 0.0117). These re-
sults indicate that in vivo, Siglec-1 expression on peripheral
blood monocytes is up-regulated by HIV-1 infection, but
normalizes after effective antiretroviral treatment sup-
presses viral replication and the associated immune activa-
tion [17,28].
The plasma of untreated HIV-1-infected individuals
stimulates Siglec-1 expression and signals via the
type I IFN receptor
To assess if immune activating factors present in the
plasma could trigger Siglec-1 expression on myeloid cells,
we tested the capacity of such plasma to induce Siglec-1 ex-
pression on DCs derived from uninfected donors. When
we quantified the number of Siglec-1 Ab binding sites per
DC, we found that plasma from untreated HIV-1-infected
individuals triggered Siglec-1 expression to a higher extent
than plasma from HIV-1-negative individuals (Figure 4A).
Induction of Siglec-1 expression was reduced to the levelut its expression is reduced after successful antiretroviral treatment. A. Mean
lated from HIV-1-negative men and from HIV-1-infected men before
-cell count and 5 log10 HIV RNA copies/ml that changed to a median of
shows mean values and SEM from nine HIV-1-negative individuals and 16
ferences between HIV-1-negative individuals and HIV-1-infected
infected men before or after successful antiretroviral treatment.
uals before (red dots) and after (green dots) antiretroviral treatment. Cells
ean values and SEM from 16 HIV-1-infected individuals. C. Uptake of HIV-
after antiretroviral treatment. Cells were cultured with HIV-1 for 4 h at
lues and SEM of the 13 individuals from which we recovered enough
isolated from HIV-1-infected individuals before and after antiretroviral
ith HIV-1NL4–3 as in Figure 2D. Graph shows mean values and SEM from
Figure 4 The plasma of untreated HIV-1-infected individuals stimulates Siglec-1 expression and signals via type I IFN receptor. A. Mean number of Siglec-1
Ab binding sites per cell induced by the plasma of HIV-1-negative individuals and HIV-1-infected individuals before or after successful
antiretroviral treatment, respectively. DCs derived from uninfected donors were cultured for 24 h in the presence of plasma and then stained for Siglec-1.
Graph shows mean values and SEM of Siglec-1 induction in DCs from two donors that were tested in parallel with the plasmas from five HIV-1-negative
individuals and ten HIV-1-infected individuals. B. Relative blockade of Siglec-1 expression by B18R, a soluble recombinant receptor with high affinity for type
I IFNs, which inhibits Siglec-1 induction triggered by the plasmas of untreated HIV-1-infected individuals. DCs were cultured for 24 h with the respective
plasma in the presence or absence of 2 μg/ml of B18R. Values are normalized to the level of Siglec-1 induction by plasma of mock-treated cells (set at
100%). Mean changes from 100% were assessed with a one sample t-test. Representative histogram also depicts IFNα-treated DCs. C. Mean number of
Siglec-1 Ab binding sites per cell induced by the plasma of untreated HIV-1-infected individuals. DCs were cultured for 24 h in the presence of plasma
collected from patients displaying the highest levels of Siglec-1 (>5500 Ab binding sites per monocyte), intermediate levels of Siglec-1 (4000–2500 Ab
binding sites per monocyte) or the lowest levels of Siglec-1 (<1500 Ab binding sites per monocyte) and then stained for Siglec-1. Graph shows mean
values and SEM of Siglec-1 induction in DCs from two donors that were tested in parallel with the plasmas from ten HIV-1-infected individuals. Man
Whitney t-test was used to compare the differences between distinct plasmas to induce Siglec-1 expression.
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plasma from the same HIV-1-infected individuals but iso-
lated after antiretroviral treatment was used (Figure 4A).
This effect was mediated by signaling through the type I
IFN receptor, since B18R, a soluble recombinant receptor
with high affinity for type I IFNs, blocked Siglec-1 induction
triggered by plasma from untreated HIV-1-infected patients
(Figure 4B). Furthermore, addition of IFNα up-regulated
Siglec-1 expression to similar levels as the plasma from un-
treated HIV-1-infected patients (Figure 4B). Moreover,
plasma from those untreated HIV-1-infected individuals
that displayed the highest level of Siglec-1 Ab binding sites
per monocyte in peripheral blood was able to trigger
Siglec-1 expression in donor DCs to a higher extent than
plasma from individuals exhibiting lower levels of Siglec-1
(Figure 4C). Thus, the capacity to induce Siglec-1 via sol-
uble factors in the plasma of HIV-1-infected individuals is
related to Siglec-1 levels on the surface of monocytes from
the respective donor, indicating that Siglec-1 expression
in vivo is indeed regulated by soluble activation factors sig-
naling via the type I IFN receptor.
Expression of Siglec-1 on monocytes correlates with
clinical parameters
Focusing our analysis on antiretroviral treatment-naïve pa-
tients (Table 2), we found a positive correlation between
Siglec-1 expression levels on isolated monocytes and i) VLP
uptake (Figure 5A; ρ = 0.8924; P < 0.0001), ii) HIV-1 uptake(Figure 5B; ρ = 0.8069; P = 0.0009), and iii) HIV-1 trans-
infection capacity (Figure 5C; ρ = 0.7833; P = 0.0015). In
addition, Siglec-1 expression levels positively correlated
with plasma viral load (Figure 5D; ρ = 0.6673; P = 0.0002).
Conversely, Siglec-1 expression negatively correlated with
CD4+ T-cell counts (Figure 5E; ρ = −0.5236; P = 0.006).
Siglec-1 positive cells accumulate in inflamed lymphoid
tissues in areas enriched in CD4+ T cells
To establish whether Siglec-1 can be detected in lymphoid
tissues where myeloid cells establish continuous cell-to-cell
interactions that could favor viral transmission, we first
performed immunohistochemical analyses of tissues
from HIV-1 uninfected individuals. Sections from
paraffin-embedded tonsils derived from HIV-, HBV-
and HCV-negative patients were classified as inflamed
(n = 3) or non-inflamed (n = 3) based on histopatho-
logical criteria. Inflamed tonsils harbored on average
23-fold more Siglec-1-positive cells than non-inflamed
tonsils (Figure 6A), indicating a clear association be-
tween the degree of immune activation and the number
of cells expressing the trans-infection receptor.
We next assessed whether Siglec-1 expressing cells
could be detected in lymphoid tissue from an HIV-1-infected
individual who had lymph nodes removed before and
after initiation of antiretroviral treatment. Of note, this
patient also had an untreated HCV infection. Siglec-1 posi-
tive cells were detected in perivascular, sub-capsular, and
Table 2 Characteristics of the HIV-1-infected men before
initiation of antiretroviral treatment, whose samples were
used in Figure 5
PRE Antiretroviral treatment Number or Median (IQR)
Number of patients 26
Age (years) 36 (24–40)
CD4+ T-cell count (cells/μl) 338.5 (285–721)
Plasma Viral Load (Log10 HIV
RNA copies/ml)
4.3 (2.9-5.3)
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excluded from CD20-positive follicular zones (Figure 6B).
A similar pattern was observed for tissue obtained be-
fore and after initiation of therapy. Although we cannot
rule out the possibility that untreated HCV infection
sustained Siglec-1 expression, it is also conceivable that
antiretroviral drug concentrations were insufficient to
fully suppress HIV-1 replication in the lymphoid tissue ofFigure 5 Expression of Siglec-1 on monocytes correlates with clinical parame
binding sites per cell and VLP uptake of monocytes isolated from antiretrovira
count and 4.3 log10 HIV RNA copies/ml. Graph shows the linear correlatio
is denoted by ρ. B. Positive correlation between the mean number of Siglec-1
antiretroviral treatment-naïve HIV-1-infected individuals. Graph shows th
enough monocytes to perform this assay. C. Positive correlation betwe
HIV-1 trans-infection capacity of monocytes isolated from antiretroviral
correlation for the same individuals as in panel B. D. Positive correlatio
and the plasma viral load at the time of sample analysis of monocytes isolated
a linear correlation for 26 individuals. E. Negative correlation between th
cell count at the time of sample analysis of monocytes isolated from ant
linear correlation for 26 individuals.this particular individual [29,30] thus sustaining IFNα
production.
Siglec-1 mediates HIV-1 trans-infection by myeloid cells
isolated from lymphoid tissue
Detection of Siglec-1 on cells residing in lymphoid tissues
prompted us to further characterize the role of tonsil-
derived Siglec-1 positive cells in HIV-1 capture and trans-
infection ex vivo. Cells were isolated from non-inflamed
tonsils of HIV-1-uninfected individuals as depicted in
Figure 7A. After mechanical disruption, mononuclear
tonsillar cells were isolated by Ficoll-Hypaque gradient
centrifugation. T- and B-lymphocytes were subsequently
depleted with magnetic beads and the remaining cell frac-
tion was cultured in the presence of IFNα or left untreated.
FACS analysis revealed an up-regulation of Siglec-1 after
24 h of IFNα treatment.
We next isolated Siglec-1 positive cells by sorting of IFNα-
treated tonsillar cells and performed a full transcriptometers. A. Positive correlation between the mean number of Siglec-1 Ab
l treatment-naïve HIV-1-infected men, with a median of 338 CD4+ T-cell
n of 26 individuals. Pearson correlation coefficient of the population
Ab binding sites per cell and HIV-1 uptake of monocytes isolated from
e linear correlation for the 13 individuals from which we recovered
en the mean number of Siglec-1 Ab binding sites per cell and the
treatment-naïve HIV-1-infected individuals. Graph shows the linear
n between the mean number of Siglec-1 Ab binding sites per cell
from antiretroviral treatment-naïve HIV-1-infected individuals. Graph shows
e mean number of Siglec-1 Ab binding sites per cell and the CD4+ T
iretroviral treatment-naïve HIV-1-infected individuals. Graph shows a
Figure 6 Siglec-1 positive cells accumulate in inflamed lymphoid tissues in areas enriched in CD4+ T cells. A. Siglec-1 expression on sections of tonsils
surgically removed either due to acute tonsillitis (n = 3; inflamed) or obstructive hypertrophy (n = 3; non-inflamed). Graph show mean values and SEM.
Representative staining images are depicted in the right panels (magnification 40x). B. Staining images of Siglec-1 on lymph nodes surgically removed
from an HIV-1-infected individual under antiretroviral treatment. Four continuous sections were cut and labeled independently with the
following panel: anti-Siglec-1, anti-CD4, anti-CD20 or hematoxilin/eosin. Top images show perivascular distribution of Siglec-1 positive cells
and bottom images display a perifollicular and subcapsular distribution.
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RNA-seq analysis of the previous IFNα-treated myeloid
cells (DCs, macrophages and monocytes), and also to
CD4+ T cells exposed to IFNα. Hierarchical clustering of
samples on the basis of their protein coding gene expres-
sion levels revealed that sorted Siglec-1 positive tonsillar
cells clustered closer to the other myeloid cells and away
from CD4+ T cells (Figure 7B). Sorted Siglec-1 positive cells
shared almost 6000 protein coding genes with other mye-
loid cells (expressed more than 100 library size-normalized
reads per kilobase of exonic sequence, Figure 7C), among
which we found a significant enrichment of genes related
to antigen-presenting functions (Table 3). Analysis of tran-
script levels of genes related to antigen-presenting functions
revealed heterogeneous gene expression levels across indi-
vidual myeloid cells and tonsil-derived Siglec-1 positive
cells (Figure 7D). Siglec-1 was highly expressed in all cell
types (more than 2,000 library size-normalized reads per
kilobase of exonic sequence). Specific markers of tissueorigin, such as CCR7 and CCL19, were found overex-
pressed in tonsil-derived Siglec-1 positive cells (Figure 7D).
When we plotted a heat map-like representation based
on a panel of markers recently proposed for identifying dif-
ferent human mononuclear phagocyte subsets [31] tonsil-
derived Siglec-1 positive cells expressed most of those
markers, but showed a distinctive profile (Figure 7E).
Siglec-1 positive tonsillar cells expressed CD1c (BDCA1),
CD1a and CD14 (Figure 7E), which are all markers found
in other primary human myeloid cells isolated from inflam-
matory fluids [32]. Thus, the unique pattern of tonsil-
derived Siglec-1 positive cells might reflect the complexity
of classifying mononuclear phagocytes under inflammatory
conditions [31]. Overall, transcriptomic analysis indicated
that sorted Siglec-1 tonsillar cells presented a unique mye-
loid antigen-presenting cell profile.
After GO enrichment analysis, 507 GO processes were
found significantly enriched, where most of the genes (3564)
were related to cellular metabolic processes (GO:0044237).
Figure 7 Siglec-1 mediates HIV-1 trans-infection in myeloid cells isolated from lymphoid tissue. A. Workflow to enrich or isolate tonsillar myeloid cells. Red
numbers on the right are used throughout the figure to identify isolation procedure. B. Hierarchical clustering (by Spearman correlation) of IFNα-treated
sorted Siglec-1 positive tonsillar cells and primary cells based on protein-coding gene expression. C. Venn diagram of overlapping protein-coding genes in
the indicated IFNα-treated cells. D. Expression heat maps of genes with antigen-presenting cell functions shared between IFNα-treated
Siglec-1 sorted tonsillar cells and at least one myeloid cell type. Data in B-D show three donors for each cell type. E. Heat map-like representation of the
theoretical presence/absence profile reported for markers proposed for myeloid cell classification [31] in the indicated cellular subsets (dark blue: presence;
light blue: absence; blue: heterogeneous expression/unknown/unclear). Observed expression in sorted Siglec-1 tonsillar cells is also depicted (dark blue:
>1.5; light blue: <1; blue: ≥1 and ≤1.5 log10). Boxes indicate markers of inflammatory myeloid cells [32]. F. Representative FACS staining of selected myeloid
markers in sorted Siglec-1 positive cells (top) and BDCA1-positive cells (bottom). G. Uptake of VLPs by BDCA1-positive tonsillar cells exposed to IFNα or left
untreated. Cells were pre-incubated with indicated mAbs. Mean values and SEM from three experiments include cells from eight donors, assessed with a
paired t-test. H. Confocal microscopy of IFNα-treated BDCA1-positive tonsillar cells (n = 2) pulsed with HIV-1Cherry and stained for Siglec-1. Representative
viral pattern (maximum fluorescence intensity of three channels and bright field). I. HIV-1 transmission from IFNα-treated sorted BDCA1-positive tonsillar
cells to a reporter CD4+ cell line. Cells were pre-incubated with indicated mAbs. Values are normalized to the level of HIV-1 trans-infected
by isotype-treated cells. Mean values and SEM from two experiments include mixed cells from six donors, assessed with a one sample t-test.
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related to immune function, the number of genes catego-
rized in each GO function, the actual number of genes
found in the 5991 protein coding genes commonly
expressed, the expected P value and the real P value ob-
tained for the genes of interest.
Sorted Siglec-1 positive cells from IFNα-treated ton-
sils co-stained with several myeloid markers that had
been identified in the transcriptomic analysis, includ-
ing BDCA1, CD11c, HLA-DR, CCR7 and CD86(Figure 7F, top panels). However, sorted Siglec-1 posi-
tive cells could not be employed in functional assays,
since mAbs against Siglec-1 block HIV-1 capture
(Figure 1D). When we sorted BDCA1-positive cells
from IFNα-treated tonsillar cells, they also stained
positive for Siglec-1, CD11c, HLA-DR, CCR7 and
CD86 (Figure 7F, bottom panels), indicating that this
population had a comparable phenotype to that exhib-
ited by Siglec-1 positive cells and could be used for
functional assays.
Table 3 List of GO biological processes relevant for antigen-presenting cell function found significantly enriched after
Bonferroni correction in the 5991 protein coding genes commonly expressed by sorted tonsil-derived Siglec-1 positive
cells and the different types of myeloid cells exposed to IFNα
GO biological process Genes in GO process Genes found Expected P-value
Immune system process (GO:0002376) 1875 791 5,10E + 05 1,38E-27
Regulation of immune system process (GO:0002682) 1090 439 2,96E + 05 3,63E-09
Positive regulation of immune system process (GO:0002684) 636 273 1,73E + 05 2,06E-06
Defense response (GO:0006952) 1256 490 3,42E + 05 1,30E-08
Regulation of defense response (GO:0031347) 502 218 1,37E + 05 1,69E-04
Immune response (GO:0006955) 1153 476 3,14E + 05 3,06E-12
Regulation of immune response (GO:0050776) 712 303 1,94E + 05 2,89E-07
Positive regulation of immune response (GO:0050778) 428 200 1,16E + 05 2,52E-06
Activation of immune response (GO:0002253) 344 175 9,35E + 04 7,68E-08
Immune response-activating signal transduction (GO:0002757) 296 165 8,05E + 04 2,15E-10
Immune response-regulating signaling pathway (GO:0002764) 403 202 1,10E + 05 3,18E-09
Immune effector process (GO:0002252) 399 194 1,09E + 05 1,82E-07
Response to virus (GO:0009615) 250 129 6,80E + 04 7,85E-05
Innate immune response (GO:0045087) 773 362 2,10E + 05 6,72E-16
Regulation of innate immune response (GO:0045088) 246 141 6,69E + 04 4,76E-09
Positive regulation of innate immune response (GO:0045089) 178 106 4,84E + 04 1,63E-06
Activation of innate immune response (GO:0002218) 148 94 4,02E + 04 1,04E-06
Innate immune response-activating signal transduction (GO:0002758) 141 91 3,83E + 04 1,05E-06
Antigen processing and presentation (GO:0019882) 222 142 6,04E + 04 5,93E-13
Of peptide antigen (GO:0048002) 186 126 5,06E + 04 8,41E-13
Of peptide antigen via MHC class I (GO:0002474) 101 81 2,75E + 04 3,02E-10
Of exogenous antigen (GO:0019884) 172 119 4,68E + 04 1,77E-12
Of exogenous peptide antigen (GO:0002478) 170 117 4,62E + 04 5,08E-12
Of exogenous peptide antigen via MHC class I (GO:0042590) 79 64 2,15E + 04 3,07E-07
Of exogenous peptide antigen via MHC class I, TAP-dependent (GO:0002479) 75 61 2,04E + 04 9,76E-07
Pattern recognition receptor signaling pathway (GO:0002221) 138 89 3,75E + 04 1,97E-06
Toll-like receptor signaling pathway (GO:0002224) 120 80 3,26E + 04 5,80E-06
Toll-like receptor 3 signaling pathway (GO:0034138) 79 57 2,15E + 04 5,06E-04
Toll-like receptor 4 signaling pathway (GO:0034142) 95 63 2,58E + 04 1,52E-03
Toll-like receptor 9 signaling pathway (GO:0034162) 73 52 1,99E + 04 4,80E-03
TRIF-dependent toll-like receptor signaling pathway (GO:0035666) 76 54 2,07E + 04 2,56E-03
Cellular response to cytokine stimulus (GO:0071345) 457 218 1,24E + 05 3,25E-08
Cytokine-mediated signaling pathway (GO:0019221) 339 169 9,22E + 04 1,08E-06
Regulation of type I interferon production (GO:0032479) 106 78 2,88E + 04 9,02E-08
Positive regulation of type I interferon production (GO:0032481) 75 56 2,04E + 04 2,13E-04
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BDCA1-positive tonsillar cells demonstrated a higher VLP
capture capacity when compared to mock-treated
BDCA1-positive cells (Figure 7G), and was specifically
inhibited by pre-treatment with an anti-Siglec-1 mAb
(Figure 7G). Of note, neither the BDCA1-negative cell
population nor B cells, which express BDCA1 and
could thus be present in the BDCA1-positive cellfraction, were able to up-regulate VLP uptake after
IFNα treatment (Additional file 1: Figure S2). In order
to investigate HIV-1 trafficking in IFNα-treated BDCA1-
positive cells, we added fluorescent HIV-1Cherry for
4 h at 37°C and subsequently stained cells with an
anti-Siglec-1 mAb (Figure 7H). Confocal microscopy
indicated that most of these BDCA1-positive cells ac-
cumulated HIV-1Cherry within a sac-like compartment
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and monocytes (Figure 2C).
Finally, to work with highly purified cell populations,
we sorted BDCA1+CD2−CD20−-tonsillar cells cultured
in the presence of IFNα and assessed Siglec-1 involve-
ment in HIV-1 trans-infection. IFNα-activated BDCA1-
positive cells pre-treated with isotype control or specific
mAb were exposed to HIV-1 for 4 h at 37°C, extensively
washed and co-cultured with a CD4+ reporter cell line
for 2 days (Figure 7I). Trans-infection was readily ob-
served and was specifically inhibited by pre-treatment
with a mAb against Siglec-1 (Figure 7I). These results in-
dicated that ex vivo, activation of myeloid cells from ton-
sils with IFNα leads to Siglec1-dependent enhanced
HIV-1 capture and trans-infection, supporting a poten-
tial role of Siglec-1 as an important molecule that could
contribute to viral capture and trans-infection within
lymphoid tissues in HIV-1-infected individuals.
Discussion
In this report, we show that Siglec-1 on myeloid cells (i)
is up-regulated by IFNα; (ii) mediates HIV-1 capture and
trans-infection; (iii) correlates in vivo with the levels of
plasma viral load and diminishes after effective antiretro-
viral treatment, and (iv) is expressed in lymphoid tissues
in an inflammation-dependent manner where it can me-
diate HIV-1 trans-infection. Taken together, these find-
ings indicate that inflammatory processes or immune
activating signals triggered by HIV-1 replication, such as
IFNα release, stimulate Siglec-1 expression on myeloid
cells, a process that could enhance viral capture and
trans-infection of CD4+ target T cells within lymphoid
tissues. Based on our results, this mechanism may be
driven by IFNα-activated monocytes and DCs, which ex-
hibited higher Siglec-1 dependent trans-infection than
macrophages. Yet, despite the faster viral degradation of
captured virions in macrophages, Siglec-1 expression in
this cell type may facilitate productive HIV-1 cis-infec-
tion [33].
This model is consistent with our findings that in vivo
Siglec-1 expression is up-regulated on monocytes from
HIV-1-infected individuals, but diminishes after effective
antiretroviral treatment suppresses plasma viral load and
virus-induced activating signals [17,28]. Our results are
in line with previous reports showing Siglec-1 up-
regulation on circulating monocytes of HIV-1-infected
individuals with higher plasma viral loads [18,34]. How-
ever, assays performed here provide functional evidence
that monocytes isolated directly from HIV-1-infected in-
dividuals capture HIV-1 and trans-infect CD4+ target
cells. We also found that Siglec-1 expression increased
with plasma viral load and decreased with CD4+ T-cell
counts in HIV-1 infected patients. Furthermore, stimuli
present in the plasma of untreated HIV-1-infectedindividuals induced Siglec-1 expression on myeloid cells
via type I IFN receptor signaling. Overall, these data sug-
gest that Siglec-1 could become a useful biomarker to
monitor chronic immune activation driven by HIV-1
infection.
Detection of Siglec-1 within lymphoid tissues suggests
that this receptor could mediate HIV-1 capture and
transmission in these compartments. Lymphoid tissues
are the perfect scenarios to fuel novel infections, since
they are major sites of HIV-1 replication [35], where
plasmacytoid and myeloid cells accumulate during the
course of HIV-1 infection [25,26] and IFNα is detected
in lymph nodes of HIV-1-infected individuals [24]. Func-
tional assays performed here with myeloid cells isolated
from tonsils and activated with IFNα (to mimic the im-
mune activation state driven by HIV-1 infection in the
lymphoid tissues), identified Siglec-1 as a key receptor
involved in viral capture and transmission.
Conclusions
We have shown that Siglec-1 expression on distinct pri-
mary myeloid cells can be induced during chronic HIV-1
infection in vivo and contribute to systemic viral dissemin-
ation. Our results strongly support that Siglec-1 is an im-
portant molecule that could accelerate HIV-1 transmission
in the crowded cellular environment of lymphatic tissues,
where many T-cells can contact myeloid cells. Future stud-
ies aimed at blocking Siglec-1 in adequate animal models
will be required to shed light on the relative contribu-
tion of HIV-1 trans-infection to disease progression
and might offer novel therapeutic approaches to halt
HIV-1 cell-to-cell transmission.
Methods
Ethics statement
The institutional review board on biomedical research
from Hospital Germans Trias i Pujol (HUGTIP) ap-
proved this study. All patients involved in this study gave
their written informed consent to participate.
Primary cells
Peripheral blood mononuclear cells (PBMCs) were ob-
tained from HIV-1-seronegative donors by Ficoll-Hypaque
density gradient centrifugation and monocyte popula-
tions were isolated as described in [36]. Monocytes were
differentiated into DCs with 1000 U/ml of granulocyte-
macrophage colony-stimulating factor plus 1000 U/ml of
Interleukin-4 (both from R&D). In parallel, monocytes from
the same donors were differentiated into macrophages with
100 ng/ml of macrophage colony-stimulating factor (Pre-
protech). Cells were cultured for 7 days, and cytokines and
media were replaced every two days. At day five, mono-
cytes, DCs and macrophages were stimulated with 1000
U/ml of Interferon-2α (Sigma-Aldrich) for two days.
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of patients with samples collected before and after anti-
retroviral treatment. Patient’s characteristics are de-
scribed in Table 1. HIV-1-negative males matched for
age were included as healthy controls. To perform func-
tional assays, PBMCs were thawed and monocytes were
isolated with CD14+ magnetic beads (Miltenyi Biotec).
Of note, positive isolation did not up-regulate Siglec-1
expression.
Human tonsils were removed during tonsillectomies of
individuals undergoing prescribed surgery at the HUGTIP.
After mechanical disruption, mononuclear tonsillar cells
were isolated by Ficoll-Hypaque gradient centrifuga-
tion. T- and B-lymphocytes were subsequently depleted
with magnetic beads against CD3+ and CD19+ (Milte-
nyi Biotec) prior blocking of the Fc receptor (Miltenyi
Biotec). Siglec-1 positive cells were sorted by isolating
Siglec-1+/CD20−/CD2−cells with mAbs7–239 α-Siglec-1-PE
(AbD Serotec), α-CD2-PerCP and α-CD20-PerCP (both
from Becton Dickinson) in a FACSVantage SE after block-
ing Fc receptors with 1 mg/ml of human IgGs (hIgGs; Pri-
vigen, Behring CSL). Myeloid cells were also isolated either
by BDCA1 positive selection with magnetic beads (Miltenyi
Biotec) or by sorting BDCA1+/CD20−/CD2−cells using
mAb α-BDCA1-PE (Miltenyi Biotec), α-CD2-PerCP
and α-CD20-PerCP. Cells were stimulated with 1000
U/ml IFNα for 24–48 h. Isolated cells were blocked
with 1 mg/ml of hIgGs for 20 min at RT and stained
with the following mAbs: α-CD11c-APC-Cy7 (BioLe-
gend), α-CCR7-PerCP (Biolegend), α-Siglec-1-Alexa
488 (AbD Serotec), α-HLA-DR-V450 (BD), α-CD86-
FITC (BD), α-BDCA1-PECy7 (Biolegend), α-CD20-
PerCPCy5.5 (BD), α-CD3-PerCP (BD) at 4°C for 30 min.
Samples were analyzed with LSRII using FlowJo software to
evaluate collected data.
All primary cells were cultured in RPMI containing
10% fetal bovine serum (FBS), 100 U/ml of penicillin
and 100 μg/ml of streptomycin (all from Invitrogen).
Siglec-1 surface expression analysis by FACS
2x105 myeloid cells were blocked with 1 mg/ml of hIgGs
and stained with mAb 7–239 α-Siglec-1-PE or matched
isotype-PE control (AbD Serotec) at 4°C for 30 min. The
mean number of Siglec-1 mAb binding sites per cell was
obtained with a Quantibrite kit (Becton Dickinson) as
previously described [9]. Samples were analyzed with
FACSCalibur using CellQuest software to evaluate col-
lected data.
Induction of Siglec-1 expression by plasmas of HIV-1-
negative individuals and HIV-1-infected individuals before
or after successful antiretroviral treatment was assessed on
2x105 DCs derived from HIV-1-negative donors cultured
for 24 h in the presence of 2% of each respective plasma.
To block Siglec-1 induction by these plasmas, carrier-freerecombinant B18R protein (eBioscience) was added at
2 μg/ml. DCs were labeled with mAb 7–239 α-Siglec-1-PE
and quantified by Quantibrite. Basal values of Siglec-1 in
DCs non-exposed to plasma were subtracted for each
sample.
Plasmids, viral stocks and cell lines
HEK-293 T and TZM-bl (obtained through the US Na-
tional Institutes of Health [NIH] AIDS Research and
Reference Reagent Program) were maintained in D-MEM
containing 10% FBS, 100 U/ml of penicillin and 100 μg/ml
of streptomicin.
HIV-1NL4–3 and VLP (VLPHIV-Gag-eGFP) stocks were
generated by transfecting the molecular clones pNL4-3
and pGag-eGFP obtained from the NIH AIDS Research
and Reference Reagent Program. HIVNL4–3-Cherry was
obtained by cotransfection of pCHIV and pCHIVm-
Cherry [37] (kindly provided by Dr. B. Muller). HEK-
293 T cells were transfected with calcium phosphate
(CalPhos, Clontech) in T75 flasks using 30 μg of plasmid
DNA. Supernatants containing virus or VLPs were filtered
(Millex HV, 0.45 μm; Millipore) and frozen at −80°C until
use. The p24Gag content of the infectious viral stocks and
VLPs was determined by an ELISA (Perkin-Elmer). HIV-
1NL4–3 used in infectious assays was titrated employing
the TZM-bl reporter cell line that expresses luciferase
under control of the HIV-1 promoter, as described in [38].
VLP and HIV-1 binding and uptake assays
Cells were pre-incubated at 4°C for 30 min with 10 μg/ml
of the functional grade mAbα-Siglec-1 7–239, IgG1 isotype
control (all from AbD Serotec) or left untreated. Binding
was performed at 4°C while uptake was done at 37°C. To
assess HIV-1NL4–3 binding and uptake, 4x10
5 cells were
pulsed with 970 ng of p24 for 4 h. After extensive washing,
cells were lysed with 0.5% Triton X-100 to measure p24Gag
antigen content by an ELISA. To analyze viral degradation,
cells were pre-incubated with 250 nM of bafilomycin A1
(Sigma) during 30 min at 37°C and then exposed to
HIVNL43 in the presence of the drug or left untreated. To
determine VLP binding and uptake, 2x105 myeloid cells
were pulsed with 10 ng of VLPs for 3 h and analyzed by
FACS.
HIV-1 trans-infection assays
Myeloid cells were treated and pulsed with HIV-1NL4–3
as described above. After extensive washing, cells were
co-cultured with the reporter cell line TZM-bl at a ratio
1:1 or 5:1. Cells were assayed for luciferase activity 48 h
later (BrightGlo luciferase system; Promega) in a Fluor-
oskan Ascent FL luminometer (Thermo Labsystems).
Background values consisting of non-HIV-1 pulsed co-
cultures were measured for each experiment. Of note,
we chose the X4-tropic virus NL4-3 and short period
Pino et al. Retrovirology  (2015) 12:37 Page 13 of 15co-culture assays to avoid productive cis-infection of
myeloid cells and focus on trans-infection.
Confocal microscopy analysis
4x105 myeloid cells were pulsed with HIV-1Gag-Cherry for
4 h at 37°C as previously described [9]. After extensive
washing, cells were fixed and permeabilized (Fix & Perm;
Invitrogen) and stained with mAbs α-Siglec-1 7–239
Alexa 488 (AbD Serotec), α-HLA-DR-Alexa 647 (Clone
L243, Biolegend) and DAPI for 30 min. Cells were cytos-
pun into coverslips and analyzed with an Ultraview ERS
Spinning Disk System (Perkin-Elmer) mounted on a
Zeiss Axiovert 200 M inverted microscope. Volocity
software (Perkin-Elmer) was used to analyze microscopy
images as in [13].
Paraffinized tissues and immunoenzyme staining
Paraffinized tonsils from HIV-1 non-infected individuals
were provided by the tissue bank of the National Center
for Tumor Diseases (Heidelberg, Germany) and ap-
proved by the ethics committee of Heidelberg University
(approval No. 206/2005). Immunoenzyme staining of
Siglec-1 were performed on 2-μm paraffin sections of
formalin-fixed tissues in principle as reported [39]. Anti-
gen retrieval was achieved by steam cooking the slides in
10 mM citrate buffer (pH 6.1, Dako) for 30 min. 10%
Earle’s balanced salt solution (EBSS, Sigma Aldrich) sup-
plemented with 1% HEPES, 0.2% bovine serum albumin,
and 0.1% saponin (all from Sigma) at pH 7.4 was used as
washing and permeabilization buffer. Primary mAb dilu-
tions with α-Siglec-1 7D2 (Novus Biologicals) were also
prepared in this buffer and incubated overnight at 4°C.
Slides were blocked in 15% sheep serum for 20 min and
revealed by biotinylated sheep anti-mouse Ab for 30 min
at RT. Immunoenzyme staining was performed with
standard avidin-biotin anti-alkaline phosphatase tech-
niques (Vectastain). Naphthol AS-biphosphate (Sigma)
with New Fuchsin (Merck) was used as the substrate for
alkaline phosphatase. Slides were viewed with an Olym-
pus BX45 microscope. Tonsils were classified by an ex-
perienced pathologist as inflamed based on strong tissue
infiltration of neutrophil granulocytes.
Paraffinized axillary and abdominal lymph nodes from
an HIV/HCV co-infected patient were analyzed at the
Pathology Department of HUGTIP. For immunohisto-
chemistry, 4-μm paraffin-embedded sections were cut,
deparaffinized and rehydrated through xylene and
graded alcohols to water. Antigen retrieval was done im-
mersing the slides for 40 minutes in EDTA Buffer in a
water bath at 98°C. The staining was performed using as
primary mAbs α-Siglec-1 7D2, α-CD4 (Clone SP35, Ven-
tana Medical Systems) and α-CD20cy (Clone L26,
DAKO) and the Ventana Discovery XT automated
stainer (Ventana Medical Systems,) with ultraViewUniversal DAB Detection Kit. Of note, patient had been
treated with two nucleoside reverse transcriptase inhibi-
tors for 7 years and had stopped treatment for 4 years,
when the first biopsy was performed. At that time point,
HIV-1 plasma viral load was < 50 HIV-1 RNA copies/ml
and CD4+ T cell-count was 485. Patient started anti-
retroviral treatment again with a protease inhibitor-
based regimen and had a second biopsy one year later,
when HIV-1 plasma viral load was <25 HIV-1 RNA cop-
ies/ml and CD4+ T cell-count was 511. At the second bi-
opsy, HCV viral load was 641.144 UI/ml.
Transcriptome RNA-seq analysis
RNA extraction from IFNα-treated DCs, macrophages
and monocytes cells (1–6 x106) was performed using
RNeasy Mini kit (Qiagen). RNA extraction from sorted
IFNα-treated Siglec-1 tonsillar cells was performed using
RNeasy Micro kit (Qiagen). mRNA-Seq library prepar-
ation was done with TruSeq RNA sample prep kit, Illu-
mina (starting with capture of polyA-containing
transcripts), followed by cluster generation (TruSeq
single-end cluster generation kit, Illumina) and high-
throughput sequencing on Illumina HiSeq2000 at the
Genomics Technology Facility, University of Lausanne.
The 100 bp single-end reads obtained were cleaned be-
fore alignment as described in [40]. Cleaned reads were
aligned to the human reference genome with STAR
aligner [41] using the ensembl gene GRCh37 release 70
annotation file. The number of reads per gene was quan-
tified with HTSeq-count v.0.6.1 [42] with parameters
mode = union and type = exon. We obtained an average
library size of 45072173 uniquely mapped reads. All
downstream analyses were performed taking as gene ex-
pression values the log10 of the number of library size-
normalized reads per kilobase of exonic sequence. A
pseudo-count of 1 was added previous to the log10 trans-
formation to avoid NA’s (impossible log transformation)
and obtain a numerical value.
Statistical analysis
We analyzed mean changes using a paired t-test, which was
considered significant at P < 0.05. Mean changes of un-
paired observations were assessed using the Man Whitney
t-test, which was considered significant at P < 0.05. Signifi-
cant mean changes from 100% of the data normalized to
percentages were assessed with a one sample t-test, consid-
ered significant at P < 0.04. Pearson correlation tests were
used to determine the level of association between Siglec-1
Ab binding sites per monocyte and VLP capture, HIV-1
capture, HIV-1 trans-infection, plasma viral load or CD4+
T-cell counts from HIV-1-infected individuals. All analyses
and figures were generated with the GraphPad Prism v5.0b
Software.
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Additional file 1: Figure S1. Siglec-1 mediates VLP capture by IFNα-
treated myeloid cells. A. Comparative binding of fluorescent VLPs to different
myeloid cells previously exposed to IFNα. Cells were pulsed with VLPs
for 3 h at 4°C and then assessed by FACS to measure the geometric
mean fluorescence intensity (MFI). B. Relative binding of VLPs by different
IFNα- treated myeloid cells pre-incubated with 10 μg/ml of the indicated
mAbs. Values are normalized to the level of VLP bound by mock-treated cells
(set at 100%). C. Uptake of fluorescent VLPs by myeloid cells exposed to IFNα.
Cells were pulsed with VLPs for 3 h at 37°C and assessed by FACS to measure
the geometric MFI. D. Relative uptake of VLPs by IFNα-treated myeloid cells
pre-incubated with 10 μg/ml of the indicated mAbs. Values are normalized to
the level of VLP captured by mock-treated cells. All panels show mean values
and SEM from 2 experiments including cells from 6 donors. Statistical
differences were assessed with a paired t test in A, and with a one
sample t-test in B and D. Figure S2. VLP uptake is not augmented in
either tonsillar BDCA1-negative cells or B cells exposed to IFNα. A. Uptake of
VLPs by CD19–/CD3–/BDCA1–-tonsillar cells previously exposed to IFNα or left
untreated. Cells were pre-incubated with 10 μg/ml of the indicated mAbs.
Mean values and SEM from 2 experiments include cells from 5 donors.
B. Uptake of VLPs by CD19+ tonsillar cells previously exposed to IFNα or
left untreated. Cells were pre-incubated with 10 μg/ml of the indicated
mAbs. Mean values and SEM include cells from 2 donors.
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